Table II.
Patient | Total daily cyclophosphamide dose (mg) |
Cyclophosphamide AUC (mcg/ mL * hr) |
DNA adduct AUC (adducts/ 10^6 nucleotides * hr) |
Ratio of DNA adduct AUC /cyclophosphamide AUC |
---|---|---|---|---|
Non-FA n=9 | ||||
1 | 5640 | 515.3 | 96.7 | 0.19 |
2 | 4000 | 529.2 | 142.8 | 0.27 |
3 | 4600 | 659.6 | 425.3 | 0.64 |
4 | 3700 | 908.7 | 276.0 | 0.30 |
5 | 2750 | 868.0 | 19.0 | 0.02 |
6 | 3000 | 647.4 | 33.5 | 0.05 |
7 | 4450 | 463.0 | 50.8 | 0.11 |
8 | 3400 | 961.0 | 147.0 | 0.15 |
9 | 3000 | 300.6 | 177.4 | 0.59 |
Median (range) | 3850 (2750–5640) | 659.6 (300.6–908.7) | 144.9 (19.0–425.3) | 0.20 (0.02–0.64) |
FA n=9 | ||||
1 | 115 | 4.2 | 64.3 | 15.16 |
2 | 195 | 8.1 | 36.1 | 4.43 |
3 | 210 | 82.3 | 26.3 | 0.32 |
4 | 206 | 167.5 | 171.3 | 1.02 |
5 | 100 | 134.9 | 148.7 | 1.10 |
6 | 95 | 39.7 | 141.2 | 3.55 |
7 | 165 | 81.6 | 271.5 | 3.33 |
8 | 93 | 49.3 | 72.4 | 1.47 |
9 | 190 | 33.6 | 99.8 | 2.97 |
Median (range) | 140 (93–210) | 49.3 (4.2–167.5) | 99.8 (26.3–271.5) | 3.0 (0.32–15.16) |
p-value* | <0.001 | <0.001 | 0.47 | 0.05 |
P-values are comparison of non-FA and FA pharmacokinetic measures.